← All trials
NCT06259006
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2024
- Primary completion
- May 31, 2027
- Completion date
- May 31, 2028
- First posted
- Feb 14, 2024
- Last posted
- Apr 11, 2024
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Starship Children's HealthLead sponsor
- Health Research Council, New ZealandCollaborator
- Menzies School of Health ResearchCollaborator
- Starship Children's HealthSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.